HKD 0.07
(-5.71%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | -412.25 Million | -13.5 Million | 252.14 Million | 400.5 Million | -149.07 Million | -18.68 Million |
Net Income | -192.71 Million | 265.17 Million | -326.26 Million | -217.71 Million | -202.37 Million | -122.4 Million |
Depreciation & Amortization | 21.86 Million | 23.55 Million | 24.43 Million | 28.4 Million | 34.71 Million | 34.28 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | -450.05 Million | -427.02 Million | 468.51 Million | 590.07 Million | -29.78 Million | 1.08 Million |
Other non-cash items | 378.57 Million | 124.78 Million | 85.46 Million | -259 Thousand | 48.36 Million | 68.34 Million |
Investing Cash Flow | -39.11 Million | 83.95 Million | 74 Thousand | -262.28 Million | -157.34 Million | -339.12 Million |
Investments in PPE | -222 Thousand | -169.73 Million | -172 Thousand | -338.94 Million | -186.96 Million | -50.01 Million |
Acquisitions | -38.89 Million | 253.68 Million | 246 Thousand | 76.65 Million | 1.72 Million | -1.8 Million |
Investment purchases | - | - | - | -1000.00 | -30.69 Million | -13.83 Million |
Sales/Maturities of investments | - | - | - | -89.54 Million | 27.89 Million | 22.92 Million |
Other Investing Activities | 534 Thousand | 254.73 Million | 1.79 Million | 89.54 Million | 30.69 Million | -296.39 Million |
Financing Cash Flow | 351.24 Million | -310.64 Million | -78.2 Million | 90.52 Million | 343.62 Million | 343.79 Million |
Debt repayment | -351.73 Million | -309.98 Million | -78.05 Million | -91.22 Million | -343.62 Million | -170.47 Million |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | 42 Million |
Other Financing Activities | -57.81 Million | -665 Thousand | -146 Thousand | 181.75 Million | 687.24 Million | 472.26 Million |
Accounts receivables | -801 Thousand | -178 Thousand | 317 Thousand | -5.84 Million | -6.35 Million | 1.2 Million |
Accounts payables | -239.48 Million | 315.47 Million | -340.67 Million | - | - | -2.65 Million |
Inventory | 114.09 Million | 670.58 Million | -163.25 Million | -452.02 Million | -148.7 Million | -121 Thousand |
Other working capital | -323.85 Million | -1.41 Billion | 972.13 Million | 1.04 Billion | 125.27 Million | 2.65 Million |
Cash at beginning of period | 251.92 Million | 486.57 Million | 338.67 Million | 91.86 Million | 54.27 Million | 70.41 Million |
Cash at end of period | 145.28 Million | 251.92 Million | 486.57 Million | 338.67 Million | 91.86 Million | 54.27 Million |
Capital Expenditure | -222 Thousand | -169.73 Million | -172 Thousand | -338.94 Million | -186.96 Million | -50.01 Million |
Effect of forex changes on cash | -316 Thousand | -4.28 Million | 2.14 Million | 4.03 Million | 396 Thousand | -2.13 Million |
Net cash flow / Change in cash | -106.64 Million | -234.65 Million | 147.9 Million | 246.8 Million | 37.59 Million | -16.14 Million |
Free Cash Flow | -412.47 Million | -183.23 Million | 251.97 Million | 61.56 Million | -336.04 Million | -68.7 Million |
Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -88.18 Million | -79.3 Million | -192.71 Million | -113.4 Million | 265.17 Million | 99.34 Million |
Depreciation & Amortization | 10.31 Million | 11.76 Million | 21.86 Million | 10.1 Million | 23.55 Million | 12.5 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | - | 85.46 Million | -450.05 Million | - | -427.02 Million | 922.34 Million |
Other non-cash items | 150.98 Million | -94.32 Million | 378.57 Million | -132.43 Million | 124.78 Million | -104.72 Million |
Investing Cash Flow | -1.01 Million | -38.92 Million | -39.11 Million | 18 Thousand | 83.95 Million | -169.62 Million |
Investments in PPE | -1.14 Million | -209 Thousand | -222 Thousand | -13 Thousand | -169.73 Million | -169.71 Million |
Acquisitions | - | -38.92 Million | -38.89 Million | 31 Thousand | 253.68 Million | 96 Thousand |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | 131 Thousand | 202 Thousand | 534 Thousand | 332 Thousand | 254.73 Million | 496 Thousand |
Financing Cash Flow | -74.87 Million | 93.53 Million | 351.24 Million | 275.27 Million | -310.64 Million | -19.28 Million |
Debt repayment | -21.77 Million | -76.16 Million | -351.73 Million | -275.57 Million | -309.98 Million | -18.95 Million |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | -53.09 Million | 93.53 Million | -57.81 Million | -75.37 Million | -665 Thousand | -124.03 Million |
Accounts receivables | - | -801 Thousand | -801 Thousand | - | -178 Thousand | -178 Thousand |
Accounts payables | - | - | -239.48 Million | - | 315.47 Million | - |
Inventory | - | 114.09 Million | 114.09 Million | - | 670.58 Million | 670.58 Million |
Other working capital | - | -27.82 Million | -323.85 Million | - | -1.41 Billion | 251.94 Million |
Cash at beginning of period | 145.28 Million | 34.15 Million | 251.92 Million | 251.92 Million | 486.57 Million | 337.92 Million |
Cash at end of period | 10.41 Million | 145.28 Million | 145.28 Million | 201.7 Million | 251.92 Million | 251.92 Million |
Capital Expenditure | -1.14 Million | -209 Thousand | -222 Thousand | -13 Thousand | -169.73 Million | -169.71 Million |
Effect of forex changes on cash | -187 Thousand | 1 Million | -316 Thousand | -1.32 Million | -4.28 Million | -970 Thousand |
Net cash flow / Change in cash | -134.87 Million | 111.12 Million | -106.64 Million | -50.21 Million | -234.65 Million | -85.99 Million |
Free Cash Flow | 71.96 Million | -76.61 Million | -412.47 Million | -255.94 Million | -183.23 Million | -187.6 Million |
214320
APGN
TGGI
APX
MED
QIPT